Contrasting Jounce Therapeutics (JNCE) & Ultragenyx Pharmaceutical (RARE)

Jounce Therapeutics (NASDAQ: JNCE) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.


This table compares Jounce Therapeutics and Ultragenyx Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jounce Therapeutics -22.76% -10.24% -5.47%
Ultragenyx Pharmaceutical N/A -76.39% -64.67%

Analyst Ratings

This is a breakdown of current ratings for Jounce Therapeutics and Ultragenyx Pharmaceutical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jounce Therapeutics 0 0 3 0 3.00
Ultragenyx Pharmaceutical 0 6 13 0 2.68

Jounce Therapeutics currently has a consensus price target of $31.50, suggesting a potential upside of 15.30%. Ultragenyx Pharmaceutical has a consensus price target of $68.94, suggesting a potential upside of 26.66%. Given Ultragenyx Pharmaceutical’s higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Jounce Therapeutics.

Volatility and Risk

Jounce Therapeutics has a beta of 8, meaning that its share price is 700% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.

Institutional and Insider Ownership

90.8% of Jounce Therapeutics shares are held by institutional investors. Comparatively, 87.2% of Ultragenyx Pharmaceutical shares are held by institutional investors. 9.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Jounce Therapeutics and Ultragenyx Pharmaceutical’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Jounce Therapeutics $71.64 million 12.35 -$16.44 million ($0.55) -49.67
Ultragenyx Pharmaceutical $2.61 million 1,034.59 -$302.13 million ($7.11) -7.66

Jounce Therapeutics has higher revenue and earnings than Ultragenyx Pharmaceutical. Jounce Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.


Jounce Therapeutics beats Ultragenyx Pharmaceutical on 8 of the 13 factors compared between the two stocks.

About Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply